Nova Mentis Life Science Corp. (NMLSF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.22 Million CAD | 50.35% |
| 2022 | -2.46 Million CAD | 8.15% |
| 2021 | -2.68 Million CAD | 88.45% |
| 2020 | -23.24 Million CAD | -1562.91% |
| 2019 | -1.39 Million CAD | 60.87% |
| 2018 | -3.57 Million CAD | -91.49% |
| 2017 | -1.86 Million CAD | 10.09% |
| 2016 | -2.07 Million CAD | -201.13% |
| 2015 | -689.15 Thousand CAD | 66.56% |
| 2014 | -2.06 Million CAD | -682.75% |
| 2013 | -263.29 Thousand CAD | 96.01% |
| 2012 | -6.59 Million CAD | -99.14% |
| 2011 | -3.31 Million CAD | -30.59% |
| 2010 | -2.53 Million CAD | -42.34% |
| 2009 | -1.78 Million CAD | -252.45% |
| 2008 | -505.68 Thousand CAD | 2.03% |
| 2007 | -516.15 Thousand CAD | -490.57% |
| 2006 | -87.4 Thousand CAD | -39.7% |
| 2005 | -62.56 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -144.37 Thousand CAD | 31.1% |
| 2024 Q2 | -90.57 Thousand CAD | 37.26% |
| 2023 Q4 | -209.56 Thousand CAD | -13.85% |
| 2023 Q3 | -184.06 Thousand CAD | 39.21% |
| 2023 FY | -1.22 Million CAD | 50.35% |
| 2023 Q1 | -528 Thousand CAD | 50.62% |
| 2023 Q2 | -302.79 Thousand CAD | 42.65% |
| 2022 Q2 | -366.78 Thousand CAD | 41.49% |
| 2022 FY | -2.46 Million CAD | 8.15% |
| 2022 Q4 | -1.06 Million CAD | -165.36% |
| 2022 Q3 | -402.93 Thousand CAD | -9.86% |
| 2022 Q1 | -626.93 Thousand CAD | -157.35% |
| 2021 Q2 | -420.96 Thousand CAD | 31.76% |
| 2021 Q1 | -616.89 Thousand CAD | 96.16% |
| 2021 Q4 | -243.6 Thousand CAD | 82.64% |
| 2021 FY | -2.68 Million CAD | 88.45% |
| 2021 Q3 | -1.4 Million CAD | -233.32% |
| 2020 Q1 | -183.78 Thousand CAD | 26.65% |
| 2020 Q4 | -16.08 Million CAD | -2800.87% |
| 2020 Q2 | -6.42 Million CAD | -3396.18% |
| 2020 Q3 | -554.49 Thousand CAD | 91.37% |
| 2020 FY | -23.24 Million CAD | -1562.91% |
| 2019 Q3 | -343.87 Thousand CAD | 26.92% |
| 2019 Q4 | -250.54 Thousand CAD | 27.14% |
| 2019 Q2 | -470.52 Thousand CAD | -41.24% |
| 2019 FY | -1.39 Million CAD | 60.87% |
| 2019 Q1 | -333.13 Thousand CAD | 39.4% |
| 2018 Q3 | -755.38 Thousand CAD | -288.02% |
| 2018 FY | -3.57 Million CAD | -91.49% |
| 2018 Q4 | -549.69 Thousand CAD | 27.23% |
| 2018 Q1 | -2.07 Million CAD | -160.26% |
| 2018 Q2 | -194.67 Thousand CAD | 90.61% |
| 2017 FY | -1.86 Million CAD | 10.09% |
| 2017 Q4 | -796.62 Thousand CAD | -70.15% |
| 2017 Q3 | -468.18 Thousand CAD | -39.85% |
| 2017 Q2 | -334.78 Thousand CAD | -25.77% |
| 2017 Q1 | -266.18 Thousand CAD | 83.34% |
| 2016 Q4 | -1.59 Million CAD | -723.42% |
| 2016 Q3 | -194.05 Thousand CAD | 2.08% |
| 2016 Q2 | -198.17 Thousand CAD | -132.62% |
| 2016 Q1 | -85.19 Thousand CAD | 64.39% |
| 2016 FY | -2.07 Million CAD | -201.13% |
| 2015 Q2 | -111.28 Thousand CAD | 33.65% |
| 2015 FY | -689.15 Thousand CAD | 66.56% |
| 2015 Q4 | -239.25 Thousand CAD | -40.0% |
| 2015 Q1 | -167.71 Thousand CAD | 90.34% |
| 2015 Q3 | -170.89 Thousand CAD | -53.57% |
| 2014 Q1 | -72.51 Thousand CAD | 20.6% |
| 2014 Q2 | -133.05 Thousand CAD | -83.49% |
| 2014 FY | -2.06 Million CAD | -682.75% |
| 2014 Q4 | -1.73 Million CAD | -1358.89% |
| 2014 Q3 | -119.01 Thousand CAD | 10.55% |
| 2013 Q4 | -91.32 Thousand CAD | -0.98% |
| 2013 Q3 | -90.43 Thousand CAD | -269.65% |
| 2013 Q2 | -24.46 Thousand CAD | 57.13% |
| 2013 Q1 | -57.06 Thousand CAD | 99.06% |
| 2013 FY | -263.29 Thousand CAD | 96.01% |
| 2012 FY | -6.59 Million CAD | -99.14% |
| 2012 Q4 | -6.09 Million CAD | -2801.3% |
| 2012 Q3 | -210.18 Thousand CAD | -77.75% |
| 2012 Q2 | -118.24 Thousand CAD | 31.0% |
| 2012 Q1 | -171.36 Thousand CAD | 92.93% |
| 2011 Q2 | -451.35 Thousand CAD | -102.25% |
| 2011 FY | -3.31 Million CAD | -30.59% |
| 2011 Q3 | -214.78 Thousand CAD | 52.41% |
| 2011 Q1 | -223.16 Thousand CAD | 69.31% |
| 2011 Q4 | -2.42 Million CAD | -1028.51% |
| 2010 FY | -2.53 Million CAD | -42.34% |
| 2010 Q3 | -314.64 Thousand CAD | -89.7% |
| 2010 Q2 | -165.86 Thousand CAD | 87.52% |
| 2010 Q4 | -727.18 Thousand CAD | -131.11% |
| 2010 Q1 | -1.32 Million CAD | -295.89% |
| 2009 Q4 | -335.76 Thousand CAD | 27.32% |
| 2009 Q1 | -607.23 Thousand CAD | -1281.36% |
| 2009 FY | -1.78 Million CAD | -252.45% |
| 2009 Q2 | -377.28 Thousand CAD | 37.87% |
| 2009 Q3 | -462 Thousand CAD | -22.45% |
| 2008 Q3 | -318.57 Thousand CAD | -69.66% |
| 2008 FY | -505.68 Thousand CAD | 2.03% |
| 2008 Q1 | -50.73 Thousand CAD | 77.47% |
| 2008 Q4 | 51.4 Thousand CAD | 116.13% |
| 2008 Q2 | -187.77 Thousand CAD | -270.14% |
| 2007 Q2 | -94.83 Thousand CAD | 1.91% |
| 2007 Q3 | -99.46 Thousand CAD | -4.89% |
| 2007 Q4 | -225.17 Thousand CAD | -126.38% |
| 2007 FY | -516.15 Thousand CAD | -490.57% |
| 2007 Q1 | -96.67 Thousand CAD | -140.64% |
| 2006 FY | -87.4 Thousand CAD | -39.7% |
| 2006 Q4 | -40.17 Thousand CAD | -137.54% |
| 2006 Q3 | -16.91 Thousand CAD | -11.59% |
| 2006 Q2 | -15.15 Thousand CAD | 0.0% |
| 2006 Q1 | -15.15 Thousand CAD | 0.0% |
| 2005 FY | -62.56 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.367% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 81.381% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.459% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.311% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.88% |
| Mesoblast Limited | -87.95 Million USD | 98.608% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 32.744% |
| Genus plc | 7.9 Million USD | 115.499% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 88.758% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 66.999% |
| Marizyme, Inc. | -65.34 Million USD | 98.126% |
| ContraFect Corporation | -65.15 Million USD | 98.121% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 86.155% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 74.941% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 29.12% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 57.668% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 84.808% |
| MultiCell Technologies, Inc. | -380.07 USD | -322056.971% |
| Accustem Sciences Inc. | -3.74 Million USD | 67.318% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.631% |
| EV Biologics, Inc. | -1.26 Million USD | 3.371% |
| Q BioMed Inc. | -2.05 Million USD | 40.333% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 67.2% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -93.613% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 48.572% |
| Biomind Labs Inc. | -1.21 Million USD | -0.832% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 88.392% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 84.507% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.747% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 43.57% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -8075.895% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 82.465% |
| IMV Inc. | -36.48 Million USD | 96.644% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 92.285% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 78.952% |
| GB Sciences, Inc. | -1.36 Million USD | 10.08% |
| Alpha Cognition Inc. | -13.77 Million USD | 91.11% |
| HST Global, Inc. | -146.21 Thousand USD | -737.441% |
| CSL Limited | 2.64 Billion USD | 100.046% |
| Halberd Corporation | -79.67 Thousand USD | -1436.751% |
| Enzolytics Inc. | -2.17 Million USD | 43.752% |
| Resverlogix Corp. | -3.61 Million USD | 66.082% |
| Affymax, Inc. | -14.42 Million USD | 91.511% |
| SYBLEU INC | -180.3 Thousand USD | -579.088% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 61.392% |
| argenx SE | -295.05 Million USD | 99.585% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.044% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1349.41% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 69.181% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 59.538% |
| AVAX Technologies, Inc. | -6.41 Million USD | 80.909% |
| Zenith Capital Corp. | -10.59 Million USD | 88.444% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.718% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5168.144% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 70.467% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1925.827% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.95% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 60.525% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -15.943% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 37.185% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 67.939% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 38.935% |
| BioStem Technologies, Inc. | -8.48 Million USD | 85.566% |
| ONE Bio Corp. | 8.67 Million USD | 114.112% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -177.415% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 8.313% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 30.223% |
| Agentix Corp. | -1.37 Million USD | 10.9% |
| LadRx Corporation | 400.44 Thousand USD | 405.767% |
| Cell Source, Inc. | -5.32 Million USD | 76.99% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -194.701% |
| Regen BioPharma, Inc. | 1.02 Million USD | 219.63% |
| Regen BioPharma, Inc. | 1.02 Million USD | 219.63% |
| NovAccess Global Inc. | -4.76 Million USD | 74.326% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 117.682% |
| Itoco Inc. | -1.86 Million USD | 34.488% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 72.439% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 26.637% |
| Kadimastem Ltd | -3.3 Million USD | 62.979% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -347.847% |
| CytoDyn Inc. | -49.84 Million USD | 97.543% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1449.254% |
| Mobile Lads Corp. | -2.26 Million USD | 45.901% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -436.728% |
| Qrons Inc. | -789.34 Thousand USD | -55.118% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -30.046% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 41.35% |
| Rebus Holdings, Inc. | -1.02 Million USD | -20.041% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 24.078% |
| International Stem Cell Corporation | -131 Thousand USD | -834.673% |
| Bioxytran, Inc. | -4.28 Million USD | 71.392% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2156.084% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 51.609% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.453% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 42.08% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -56.799% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 61.35% |
| Neutra Corp. | -233.46 Thousand USD | -424.456% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.966% |
| PureTech Health plc | -65.69 Million USD | 98.136% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 94.242% |
| IXICO plc | -1.17 Million USD | -3.941% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 87.666% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.857% |
| CSL Limited | 2.64 Billion USD | 100.046% |
| Cellectis S.A. | -103.17 Million USD | 98.813% |